Therefore, adenocarcinoma patients were divided into two groups depending on the sPD-L1 level, i.e., a group with low sPD-L1 (≤182.5 ng/L) and a group with high sPD-L1 (>182.5 ng/L). Here, SPDL1 is linked to adenocarcinoma.